Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	guanylate cyclase activity	NPR2 GUCY1B2 GUCY2F	4.52e-05	10	147	3	GO:0004383
GeneOntologyBiologicalProcess	cell morphogenesis	TNIK NPR2 MYH9 ANK3 ABI3BP FAT3 NR4A2 TRIOBP AP3B1 CPNE5 ADAM8 GRHL2 ITGB2 ACTR2 STK11 HMCN2 CELSR2 SEMA3B CNTNAP2 LRP1 STRC DMD TBCD STRCP1 PROX1 SOS1	3.60e-07	1194	148	26	GO:0000902
GeneOntologyBiologicalProcess	cell morphogenesis involved in neuron differentiation	TNIK NPR2 ANK3 ABI3BP FAT3 NR4A2 TRIOBP ACTR2 STK11 HMCN2 CELSR2 SEMA3B CNTNAP2 LRP1 STRC TBCD STRCP1 SOS1	7.18e-06	748	148	18	GO:0048667
GeneOntologyBiologicalProcess	cell-substrate adhesion	MYH9 ABI3BP TRIOBP ITGAD ADAM8 ITGB2 PTPRK LRP1 ANTXR1 STRC DMD TBCD STRCP1	8.45e-06	410	148	13	GO:0031589
GeneOntologyBiologicalProcess	cell-cell adhesion via plasma-membrane adhesion molecules	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 ITGB2 MAGI2 HMCN2 CELSR2 CDH16 CRB2	1.67e-05	313	148	11	GO:0098742
GeneOntologyBiologicalProcess	neuron development	TNIK DPYSL3 NPR2 ANK3 ABI3BP FAT3 NR4A2 TRIOBP CPNE5 ACTR2 MAGI2 STK11 HMCN2 CELSR2 PTPRK CSPG4 SEMA3B CNTNAP2 LRP1 STRC DMD TBCD CRB2 STRCP1 SOS1	4.26e-05	1463	148	25	GO:0048666
GeneOntologyBiologicalProcess	neuron projection development	TNIK DPYSL3 NPR2 ANK3 ABI3BP FAT3 NR4A2 TRIOBP CPNE5 ACTR2 MAGI2 STK11 HMCN2 CELSR2 PTPRK CSPG4 SEMA3B CNTNAP2 LRP1 STRC DMD STRCP1 SOS1	4.44e-05	1285	148	23	GO:0031175
GeneOntologyBiologicalProcess	homophilic cell adhesion via plasma membrane adhesion molecules	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 HMCN2 CELSR2 CDH16	6.28e-05	187	148	8	GO:0007156
GeneOntologyBiologicalProcess	cell-cell adhesion	MYH9 ANK3 SH2B3 FAT3 PCDHB14 PCDHA11 CDHR5 ITGAD AP3B1 CLSTN1 ADAM8 ITGB2 MAGI2 HMCN2 CELSR2 TJP2 TLN2 ANXA9 CDH16 CRB2	8.95e-05	1077	148	20	GO:0098609
GeneOntologyCellularComponent	cell surface	RAMP3 ANK3 ITGAD CLSTN1 ADAM8 ITGB2 RTN2 IGF2R PTPRK CSPG4 CNTNAP2 LRP1 TJP2 ANTXR1 HTR3B STRC DMD LY9 ANXA9 MMP16 STRCP1	3.05e-05	1111	146	21	GO:0009986
GeneOntologyCellularComponent	cell leading edge	DPYSL3 MYH9 ABI3BP EPS8L1 ACTR2 RAB34 PTPRK ARHGAP31 CSPG4 CNTNAP2 ANTXR1 TLN2 DMD	5.05e-05	500	146	13	GO:0031252
GeneOntologyCellularComponent	anchoring junction	MYH9 ANK2 ANK3 TRIOBP GRHL2 ITGB2 ACTR2 MAGI2 IGF2R PTPRK ARHGAP31 CSPG4 CNTNAP2 LRP1 TJP2 TLN2 DMD TBCD CRB2	5.10e-05	976	146	19	GO:0070161
GeneOntologyCellularComponent	lamellipodium	DPYSL3 MYH9 ABI3BP ACTR2 ARHGAP31 CSPG4 ANTXR1 DMD	2.18e-04	230	146	8	GO:0030027
GeneOntologyCellularComponent	stereocilium tip	PKHD1L1 STRC STRCP1	4.66e-04	22	146	3	GO:0032426
GeneOntologyCellularComponent	costamere	ANK2 ANK3 DMD	4.66e-04	22	146	3	GO:0043034
Domain	LAM_G_DOMAIN	FAT3 CELSR2 CSPG4 CNTNAP2 CRB2	1.04e-05	38	144	5	PS50025
Domain	Laminin_G_2	FAT3 CELSR2 CSPG4 CNTNAP2 CRB2	1.35e-05	40	144	5	PF02210
Domain	LamG	FAT3 CELSR2 CSPG4 CNTNAP2 CRB2	2.17e-05	44	144	5	SM00282
Domain	CADHERIN_1	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 CELSR2 CDH16	2.73e-05	113	144	7	PS00232
Domain	CADHERIN_2	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 CELSR2 CDH16	2.89e-05	114	144	7	PS50268
Domain	-	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 CELSR2 CDH16	2.89e-05	114	144	7	2.60.40.60
Domain	CA	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 CELSR2 CDH16	3.06e-05	115	144	7	SM00112
Domain	Cadherin-like	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 CELSR2 CDH16	3.24e-05	116	144	7	IPR015919
Domain	Cadherin	FAT3 PCDHB14 PCDHA11 CDHR5 CLSTN1 CELSR2 CDH16	3.61e-05	118	144	7	IPR002126
Domain	ZU5	ANK2 ANK3 PIDD1	5.18e-05	10	144	3	PS51145
Domain	Laminin_G	FAT3 CELSR2 CSPG4 CNTNAP2 CRB2	8.38e-05	58	144	5	IPR001791
Domain	-	FAT3 CLSTN1 CELSR2 CSPG4 CNTNAP2 CRB2	9.36e-05	95	144	6	2.60.120.200
Domain	ZU5	ANK2 ANK3 PIDD1	9.38e-05	12	144	3	PF00791
Domain	ZU5_dom	ANK2 ANK3 PIDD1	9.38e-05	12	144	3	IPR000906
Domain	Cadherin_CS	FAT3 PCDHB14 PCDHA11 CDHR5 CELSR2 CDH16	2.00e-04	109	144	6	IPR020894
Domain	Cadherin	FAT3 PCDHB14 PCDHA11 CLSTN1 CELSR2 CDH16	2.43e-04	113	144	6	PF00028
Domain	ConA-like_dom	FAT3 CLSTN1 CELSR2 PTPRK CSPG4 CNTNAP2 NEURL4 CRB2	3.02e-04	219	144	8	IPR013320
Domain	Guanylate_cyc	NPR2 GUCY1B2 GUCY2F	3.97e-04	19	144	3	PF00211
Domain	GUANYLATE_CYCLASE_2	NPR2 GUCY1B2 GUCY2F	3.97e-04	19	144	3	PS50125
Domain	A/G_cyclase	NPR2 GUCY1B2 GUCY2F	3.97e-04	19	144	3	IPR001054
Domain	GUANYLATE_CYCLASE_1	NPR2 GUCY1B2 GUCY2F	3.97e-04	19	144	3	PS00452
Domain	CYCc	NPR2 GUCY1B2 GUCY2F	3.97e-04	19	144	3	SM00044
Domain	VWFA	ITGAD CPNE5 ITGB2 HMCN2 ANTXR1	4.30e-04	82	144	5	PS50234
Domain	VWA	ITGAD CPNE5 ITGB2 HMCN2 ANTXR1	4.81e-04	84	144	5	SM00327
Domain	EGF_1	FAT3 ADAM8 ITGB2 HMCN2 CELSR2 CNTNAP2 LRP1 CRB2	8.25e-04	255	144	8	PS00022
Domain	HNOB_dom_associated	GUCY1B2 GUCY2F	8.68e-04	6	144	2	IPR011645
Domain	HNOBA	GUCY1B2 GUCY2F	8.68e-04	6	144	2	PF07701
Domain	EGF-like_CS	FAT3 ADAM8 ITGB2 HMCN2 CELSR2 CNTNAP2 LRP1 CRB2	9.59e-04	261	144	8	IPR013032
Domain	VWF_A	ITGAD CPNE5 ITGB2 HMCN2 ANTXR1	1.02e-03	99	144	5	IPR002035
Domain	EGF_2	FAT3 ADAM8 ITGB2 HMCN2 CELSR2 CNTNAP2 LRP1 CRB2	1.06e-03	265	144	8	PS01186
Domain	ASX_HYDROXYL	FAT3 HMCN2 CELSR2 LRP1 CRB2	1.06e-03	100	144	5	PS00010
Domain	DEATH	ANK2 ANK3 PIDD1	1.15e-03	27	144	3	SM00005
Domain	RNA_pol_II-bd	SCAF8 PCF11	1.21e-03	7	144	2	IPR006903
Domain	CTD_bind	SCAF8 PCF11	1.21e-03	7	144	2	PF04818
Domain	EGF-type_Asp/Asn_hydroxyl_site	FAT3 HMCN2 CELSR2 LRP1 CRB2	1.38e-03	106	144	5	IPR000152
Domain	RPR	SCAF8 PCF11	1.60e-03	8	144	2	SM00582
Domain	CID_dom	SCAF8 PCF11	1.60e-03	8	144	2	IPR006569
Domain	Carboxylesterase_B_AS	CES2 CES3	1.60e-03	8	144	2	IPR019826
Domain	CID	SCAF8 PCF11	1.60e-03	8	144	2	PS51391
Domain	CARBOXYLESTERASE_B_1	CES2 CES3	1.60e-03	8	144	2	PS00122
Pubmed	A probability-based approach for high-throughput protein phosphorylation analysis and site localization.	MYH9 CAD PPAN AFTPH RRP1B USP24 DIDO1 USP5 FAM13A GMEB1 TJP2 OTUD4 TLN2 ZNF574	4.01e-08	503	149	14	16964243
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	DPYSL3 CCDC8 CAD ANK3 RRP1B TRIOBP SLC39A10 AP3B1 PCF11 NHSL1 IGF2R PTPRK SBF2 OTUD4 TAB1 DMD PUM1 CPVL NEURL4	1.32e-07	1049	149	19	27880917
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	MAN2A2 SH2B3 MFHAS1 UBR4 APEH NHSL1 BMP8B SLC38A10 IGF2R CELSR2 SBF2 CSPG4 TLN2 PUM1 CPVL MYRF UVRAG SOWAHB TBCD	2.91e-07	1105	149	19	35748872
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	AFTPH ANK3 DRAM1 UBR4 USF3 MIA2 GUCY1B2 ARHGAP31 NEURL4 UVRAG DNMT3B SOS1	3.78e-07	430	149	12	35044719
Pubmed	An ankyrin-based mechanism for functional organization of dystrophin and dystroglycan.	ANK2 ANK3 DMD	7.66e-07	5	149	3	19109891
Pubmed	CK2-regulated schwannomin-interacting protein IQCJ-SCHIP-1 association with AnkG contributes to the maintenance of the axon initial segment.	SCHIP1 ANK2 ANK3	7.66e-07	5	149	3	25950943
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	TNIK MYH9 CAD ANK2 ANK3 UBR4 TRIOBP TNRC6B DIDO1 MAGI2 IGF2R CELSR2 LRP1 OTUD4 TLN2 NEURL4 PROX1	9.00e-07	963	149	17	28671696
Pubmed	An Interaction Landscape of Ubiquitin Signaling.	UBR4 USP24 MCL1 HPDL TEFM TCEAL1 USP5 USP38 OTUD4 ANTXR1 TAB1 NEURL4	1.23e-06	481	149	12	28190767
Pubmed	Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons.	UBR4 PIDD1 USP5 GUCY1B2 MARF1 DISP3 MMS19 HTR3B DMD TBCD	1.41e-06	322	149	10	26514267
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	TNIK MYH9 CAD KCNH7 ANK2 ANK3 UBR4 USP24 TRIOBP TNRC6B MAGI2 NHSL1 RUVBL1 CELSR2 CNTNAP2 TJP2 TLN2 TAB1	2.03e-06	1139	149	18	36417873
Pubmed	Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin.	DPYSL3 MYH9 ACTR2 IGF2R LRP1 OTUD4 WDR77	3.88e-06	149	149	7	26370502
Pubmed	ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.	DPYSL3 MYH9 MAN2A2 SLC39A10 CLSTN1 B3GAT3 USP5 IGF2R MIA2 RAB34 RUVBL1 CELSR2 PTPRK CSPG4 SEMA3B LRP1 ANTXR1 CPVL	4.23e-06	1201	149	18	35696571
Pubmed	Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs.	MYH9 TNRC6B MCL1 OTUD4 TAB1 WDR77	5.07e-06	101	149	6	19167051
Pubmed	Targeted ubiquitination and degradation of G-protein-coupled receptor kinase 5 by the DDB1-CUL4 ubiquitin ligase complex.	MYH9 ABI3BP AP3B1 RUVBL1 OTUD4 MMS19 TAB1	5.25e-06	156	149	7	22952844
Pubmed	High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface.	SCAF8 MDM1 TNRC6B SLC39A10 SLC38A10 MIA2 RAB34 CELSR2 PTPRK	7.66e-06	307	149	9	37499664
Pubmed	USP45 and Spindly are part of the same complex implicated in cell migration.	DPYSL3 MYH9 CAD ABI3BP CLSTN1 CPNE5 TJP2 OTUD4	8.47e-06	235	149	8	30258100
Pubmed	Comparative interactome analysis of α-arrestin families in human and Drosophila.	TNIK CAD UBR4 USP5 RUVBL1 BOD1L1 MMS19 DMD NEURL4	8.95e-06	313	149	9	38270169
Pubmed	Genetic Hearing Loss Overview	MYH9 TRIOBP GRHL2 TJP2 STRC	1.30e-05	70	149	5	20301607
Pubmed	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.	TNIK CCDC8 ANK3 TRIOBP SLC39A10 NHSL1 IGF2R RAB34 CELSR2 DMD	1.49e-05	421	149	10	36976175
Pubmed	Frontline Science: The expression of integrin αD β2 (CD11d/CD18) on neutrophils orchestrates the defense mechanism against endotoxemia and sepsis.	ITGAD ITGB2	1.82e-05	2	149	2	33438263
Pubmed	The extracellular domain of CD11d regulates its cell surface expression.	ITGAD ITGB2	1.82e-05	2	149	2	19571252
Pubmed	Dual-vector gene therapy restores cochlear amplification and auditory sensitivity in a mouse model of DFNB16 hearing loss.	STRC STRCP1	1.82e-05	2	149	2	34910522
Pubmed	Talin2 binds to non-muscle myosin IIa and regulates cell attachment and fibronectin secretion.	MYH9 TLN2	1.82e-05	2	149	2	39215026
Pubmed	Roles of ADAM8 in elimination of injured muscle fibers prior to skeletal muscle regeneration.	ADAM8 DMD	1.82e-05	2	149	2	25511460
Pubmed	LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model.	STK11 DMD	1.82e-05	2	149	2	37427454
Pubmed	LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion.	ITGB2 LRP1	1.82e-05	2	149	2	15328156
Pubmed	Mutations in a new gene encoding a protein of the hair bundle cause non-syndromic deafness at the DFNB16 locus.	STRC STRCP1	1.82e-05	2	149	2	11687802
Pubmed	The ankyrin-B C-terminal domain determines activity of ankyrin-B/G chimeras in rescue of abnormal inositol 1,4,5-trisphosphate and ryanodine receptor distribution in ankyrin-B (-/-) neonatal cardiomyocytes.	ANK2 ANK3	1.82e-05	2	149	2	11781319
Pubmed	Structural basis of diverse membrane target recognitions by ankyrins.	ANK2 ANK3	1.82e-05	2	149	2	25383926
Pubmed	Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice.	ADAM8 PROX1	1.82e-05	2	149	2	15580619
Pubmed	Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen.	CSPG4 MMP16	1.82e-05	2	149	2	11278606
Pubmed	Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression.	CAD UBR4 RUVBL1 MARF1 OTUD4 BOD1L1 TAB1 WDR77	2.43e-05	272	149	8	31010829
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	TNIK MYH9 MAN2A2 ANK2 RRP1B TNRC6B DIDO1 TRIM71 AP3B1 TEFM PCF11 RUVBL1 MARF1 RAB2B TJP2 OTUD4 WDR77 ZNF574	2.51e-05	1371	149	18	36244648
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	DPYSL3 CAD ANK3 USP24 TNRC6B DIDO1 AP3B1 RUVBL1 TJP2 BOD1L1 TAB1	2.67e-05	549	149	11	38280479
Pubmed	SR protein kinases promote splicing of nonconsensus introns.	ANK3 RRP1B UBR4 DIDO1 EPS8L1 PCF11 HMCN2 TJP2 TLN2	2.76e-05	361	149	9	26167880
Pubmed	ABCE1 is a highly conserved RNA silencing suppressor.	ANK2 RRP1B IGF2R MMS19 CPVL WDR77 TBCD	2.99e-05	204	149	7	25659154
Pubmed	Construction of a multi-functional cDNA library specific for mouse pancreatic islets and its application to microarray.	RPS6KA4 ANK2 SH2B3 MDM1 TRIOBP ACTR2 IGF2R CNTNAP2 TJP2	3.41e-05	371	149	9	15747579
Pubmed	Cooperative polarization of MCAM/CD146 and ERM family proteins in melanoma.	TNIK ANK3 SLC39A10 RAB34 PTPRK ARHGAP31 CSPG4 DMD ATP2B3	3.86e-05	377	149	9	38117590
Pubmed	Discovery and Characterization of ZUFSP/ZUP1, a Distinct Deubiquitinase Class Important for Genome Stability.	USP24 TEFM USP5 USP38 TJP2 OTUD4	4.30e-05	147	149	6	29576527
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	MYH9 PPAN ANK2 ZNF474 ABI3BP UBR4 ACTR2 PCF11 STK11 MIA2 CSPG4 MARF1 CES3 ANTXR1 BOD1L1 DMD ATP2B3 DNMT3B	4.83e-05	1442	149	18	35575683
Pubmed	Cochlear outer hair cell horizontal top connectors mediate mature stereocilia bundle mechanics.	STRC STRCP1	5.45e-05	3	149	2	30801007
Pubmed	Human carboxylesterases: an update on CES1, CES2 and CES3.	CES2 CES3	5.45e-05	3	149	2	19508181
Pubmed	The ammonium transporter RhBG: requirement of a tyrosine-based signal and ankyrin-G for basolateral targeting and membrane anchorage in polarized kidney epithelial cells.	ANK2 ANK3	5.45e-05	3	149	2	15611082
Pubmed	Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.	IGF2R DMD	5.45e-05	3	149	2	18276788
Pubmed	Inositol pyrophosphate mediated pyrophosphorylation of AP3B1 regulates HIV-1 Gag release.	ANK3 AP3B1	5.45e-05	3	149	2	19934039
Pubmed	A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3.	ITGAD ITGB2	5.45e-05	3	149	2	8777714
Pubmed	Hematopoietic stem/progenitor cells directly contribute to arteriosclerotic progression via integrin β2.	ITGB2 LRP1	5.45e-05	3	149	2	25546260
Pubmed	On the potential involvement of CD11d in co-stimulating the production of interferon-γ by natural killer cells upon interaction with neutrophils via intercellular adhesion molecule-3.	ITGAD ITGB2	5.45e-05	3	149	2	21712539
Pubmed	Molecular basis for the interaction of low density lipoprotein receptor-related protein 1 (LRP1) with integrin alphaMbeta2: identification of binding sites within alphaMbeta2 for LRP1.	ITGB2 LRP1	5.45e-05	3	149	2	21676865
Pubmed	Human ankyrins and their contribution to disease biology: An update.	ANK2 ANK3	5.45e-05	3	149	2	33410423
Pubmed	Ankyrin-dependent Na+ channel clustering prevents neuromuscular synapse fatigue.	ANK2 ANK3	5.45e-05	3	149	2	34289389
Pubmed	In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.	MYH9 ACO1 APEH CDHR5 EPS8L1 CPNE5 ACTR2 IGF2R BPGM CSPG4 RAB2B CPVL KLK2 CDH16 CRB2	5.98e-05	1070	149	15	23533145
Pubmed	SARS-CoV-2 ORF8 Protein Induces Endoplasmic Reticulum Stress-like Responses and Facilitates Virus Replication by Triggering Calnexin: an Unbiased Study.	CAD UBR4 WDR77	6.00e-05	18	149	3	36877072
Pubmed	Fibril treatment changes protein interactions of tau and α-synuclein in human neurons.	TNIK MYH9 UBR4 USP24 APEH AP3B1 RUVBL1 TLN2 BOD1L1 TBCD	6.14e-05	498	149	10	36634849
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	TNIK SCAF8 TNRC6B SLC39A10 MFAP3L MAGI2 OTUD4 BOD1L1 PUM1	6.96e-05	407	149	9	12693553
Pubmed	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk.	NPR2 TNRC6B MAGI2	7.10e-05	19	149	3	25342443
Pubmed	An unappreciated role for RNA surveillance.	NPR2 MAN2A2 CAPN10 ANTXR1 KLK2	8.05e-05	102	149	5	14759258
Pubmed	Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.	TNIK KCNH7 ANK2 PCDHA11 BMP8B MIA2 CELSR2 SOS1	9.24e-05	329	149	8	17474147
Pubmed	Tagging genes with cassette-exchange sites.	SCAF8 UBR4 DIDO1 AP3B1 USP5 MMS19 TAF5L PUM1	1.05e-04	335	149	8	15741177
Pubmed	Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes.	DPYSL3 USP24 APEH SLC39A10 B3GAT3 NHSL1 TJP2 CPVL NEURL4 TBCD	1.07e-04	533	149	10	25544563
Pubmed	Stereocilin-deficient mice reveal the origin of cochlear waveform distortions.	STRC STRCP1	1.09e-04	4	149	2	18849963
Pubmed	c-Abl kinase is required for beta 2 integrin-mediated neutrophil adhesion.	ITGB2 TLN2	1.09e-04	4	149	2	19234221
Pubmed	Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes.	CES2 CES3	1.09e-04	4	149	2	18794728
Pubmed	Ankyrin-B interactions with spectrin and dynactin-4 are required for dystrophin-based protection of skeletal muscle from exercise injury.	ANK2 DMD	1.09e-04	4	149	2	21186323
Pubmed	Complement receptor 3 (CD11b/CD18) is implicated in the elimination of β-amyloid peptides.	ITGB2 LRP1	1.09e-04	4	149	2	20199584
Pubmed	Progesterone induced Warburg effect in HEK293 cells is associated with post-translational modifications and proteasomal degradation of progesterone receptor membrane component 1.	UBR4 USP24 USP5 PTPRK	1.15e-04	58	149	4	31067491
Pubmed	The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.	CAD RUVBL1 OTUD4 TAB1	1.23e-04	59	149	4	32382008
Pubmed	Tissue-Specific Regulation of the Wnt/β-Catenin Pathway by PAGE4 Inhibition of Tankyrase.	MYH9 CAD PPAN RUVBL1 OTUD4 TAB1 WDR77	1.24e-04	256	149	7	32698014
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	MYH9 CAD RRP1B UBR4 USP24 DIDO1 ACTR2 USP5 IGF2R TJP2 PUM1	1.25e-04	653	149	11	22586326
Pubmed	The receptor guanylyl cyclase Npr2 is essential for sensory axon bifurcation within the spinal cord.	NPR2 GUCY1B2 GUCY2F	1.28e-04	23	149	3	17954614
Pubmed	Embryonic lethality in mice lacking Trim59 due to impaired gastrulation development.	MYH9 TRIOBP ACTR2	1.28e-04	23	149	3	29467473
Pubmed	Tumor suppressor BAP1 nuclear import is governed by transportin-1.	DPYSL3 MYH9 CAD ANK3 UBR4 AP3B1 ACTR2 USP5 RUVBL1 RAB2B OTUD4 MMS19 TAB1 CPVL WDR77	1.31e-04	1149	149	15	35446349
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	PPAN AFTPH SCAF8 USP24 DIDO1 PCF11 FAM13A TJP2 OTUD4 TLN2 ANXA9 SOS1	1.34e-04	774	149	12	15302935
Pubmed	Transcription factor Tcf4 is the preferred heterodimerization partner for Olig2 in oligodendrocytes and required for differentiation.	ANK2 CSPG4 MYRF	1.65e-04	25	149	3	32266943
Pubmed	Large-scale concatenation cDNA sequencing.	SCHIP1 ANK2 UBR4 MDM1 TLN2 MMS19 LY9 MMP16 WDR77 TBCD	1.79e-04	568	149	10	9110174
Pubmed	Glial ankyrins facilitate paranodal axoglial junction assembly.	ANK2 ANK3	1.81e-04	5	149	2	25362471
Pubmed	Schwannomin-interacting protein-1 isoform IQCJ-SCHIP-1 is a late component of nodes of Ranvier and axon initial segments.	SCHIP1 ANK3	1.81e-04	5	149	2	18550753
Pubmed	Chemokine-coupled β2 integrin-induced macrophage Rac2-Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis.	MYH9 ITGB2	1.81e-04	5	149	2	25180062
Pubmed	The regulatory protein GADD34 inhibits TRAIL-induced apoptosis via TRAF6/ERK-dependent stabilization of myeloid cell leukemia 1 in liver cancer cells.	MCL1 TAB1	1.81e-04	5	149	2	30782845
Pubmed	Genetic evidence for Dnmt3a-dependent imprinting during oocyte growth obtained by conditional knockout with Zp3-Cre and complete exclusion of Dnmt3b by chimera formation.	IGF2R DNMT3B	1.81e-04	5	149	2	20132320
Pubmed	Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure.	CSPG4 PROX1	1.81e-04	5	149	2	17299096
Pubmed	Mammalian carboxylesterase 3: comparative genomics and proteomics.	CES2 CES3	1.81e-04	5	149	2	20422440
Pubmed	Deficiency of CD11b or CD11d results in reduced staphylococcal enterotoxin-induced T cell response and T cell phenotypic changes.	ITGAD ITGB2	1.81e-04	5	149	2	15210787
Pubmed	An unusually powerful mode of low-frequency sound interference due to defective hair bundles of the auditory outer hair cells.	STRC STRCP1	1.81e-04	5	149	2	24920589
Pubmed	A comprehensive resource of interacting protein regions for refining human transcription factor networks.	SCHIP1 ANK2 ANK3 USP24 NR4A2 CLSTN1	1.82e-04	191	149	6	20195357
Pubmed	A "double adaptor" method for improved shotgun library construction.	SCHIP1 ANK2 UBR4 MDM1 TLN2 MMS19 LY9 MMP16 WDR77 TBCD	1.95e-04	574	149	10	8619474
Pubmed	Mapping the Ku Interactome Using Proximity-Dependent Biotin Identification in Human Cells.	MYH9 RRP1B DIDO1 ZNF711 PCF11 RUVBL1 BOD1L1	2.30e-04	283	149	7	30585729
Pubmed	ELF a beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene.	ANK2 DMD	2.70e-04	6	149	2	12149647
Pubmed	CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics.	MYH9 ITGB2	2.70e-04	6	149	2	21659539
Pubmed	The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells.	LRP1 MMP16	2.70e-04	6	149	2	14645246
Pubmed	ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.	MYH9 ITGB2	2.70e-04	6	149	2	37069398
Pubmed	The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.	MYH9 ACTR2	2.70e-04	6	149	2	25926623
Pubmed	Mest but Not MiR-335 Affects Skeletal Muscle Growth and Regeneration.	IGF2R DMD	2.70e-04	6	149	2	26098312
Pubmed	BetaIVSigma1 spectrin stabilizes the nodes of Ranvier and axon initial segments.	ANK3 CNTNAP2	2.70e-04	6	149	2	15381686
Pubmed	Small mammalian animal models of heart disease.	STK11 DMD	2.70e-04	6	149	2	27679742
Pubmed	Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy.	CSPG4 DMD	2.70e-04	6	149	2	29772070
Pubmed	Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins.	CES2 CES3	2.70e-04	6	149	2	20931200
Pubmed	In vivo assembly of the axon initial segment in motor neurons.	ANK2 ANK3	2.70e-04	6	149	2	23728480
Pubmed	Spectrins and ankyrinB constitute a specialized paranodal cytoskeleton.	ANK2 CNTNAP2	2.70e-04	6	149	2	16687515
Pubmed	FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2.	MYH9 CAD RRP1B UBR4 DIDO1 TEFM RUVBL1 SBF2 OTUD4 PUM1	2.81e-04	601	149	10	33658012
Cytoband	22q13.1	MYH9 TRIOBP TNRC6B TAB1	1.76e-04	85	149	4	22q13.1
GeneFamily	Cadherin related	FAT3 CDHR5 CLSTN1	1.15e-04	17	103	3	24
GeneFamily	Carboxylesterases	CES2 CES3	3.18e-04	5	103	2	461
GeneFamily	Actins\|Deafness associated genes	MYH9 TRIOBP GRHL2 TJP2 STRC	4.69e-04	113	103	5	1152
GeneFamily	Guanylate cyclase receptors	NPR2 GUCY2F	6.63e-04	7	103	2	343
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro-stroma\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	DPYSL3 RAMP3 ANK2 ANK3 ABI3BP PPP1R1A CSPG4 LRP1 ANTXR1	2.43e-08	200	148	9	747c61d4e0b746278ae1f45ca4cd556c6961c76a
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	DPYSL3 RAMP3 ANK2 ANK3 ABI3BP PPP1R1A CSPG4 LRP1 ANTXR1	2.43e-08	200	148	9	de1d193f773f4e2927baa6fc38d29754b015c6e6
ToppCell	facs-Thymus-Epithelium-3m-Mesenchymal\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DPYSL3 ANK2 ABI3BP PCDHB14 TCEAL1 RAB34 SEMA3B ANTXR1	2.38e-07	189	148	8	1db5dd1ef2a65251af2d5696622d1dd9c4ae2b55
ToppCell	facs-Thymus-Epithelium-3m-Mesenchymal-fibroblast\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DPYSL3 ANK2 ABI3BP PCDHB14 TCEAL1 RAB34 SEMA3B ANTXR1	2.38e-07	189	148	8	bfb1c183a8a2752a2368b74150e66181c6a9da48
ToppCell	facs-Thymus-Epithelium-3m-Mesenchymal-fibroblast\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DPYSL3 ANK2 ABI3BP PCDHB14 TCEAL1 RAB34 SEMA3B ANTXR1	2.38e-07	189	148	8	14833feea8f80744a06ece73f813eaeff8c4dd61
ToppCell	356C-Endothelial_cells-Endothelial-E\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	DIDO1 ADAM8 QRICH2 CAPN10 HMCN2 ANTXR1 TAB1	1.60e-06	169	148	7	0425d2580ed325178f522c0093ff4623de6ce7a8
ToppCell	356C-Endothelial_cells-Endothelial-E-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	DIDO1 ADAM8 QRICH2 CAPN10 HMCN2 ANTXR1 TAB1	1.60e-06	169	148	7	fec669968a77060bd77ee8695034e35a642c984f
ToppCell	3'-GW_trimst-2-SmallIntestine-Mesenchymal-mesothelial_cell\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SERPINE3 LIPF EPS8L1 PKHD1L1 ANXA9 MYRF CRB2	2.34e-06	179	148	7	056df2aaff750e0e283e7da78fcc3c90c366aac0
ToppCell	3'-GW_trimst-2-SmallIntestine-Mesenchymal-mesothelial_cell-Mesothelium\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SERPINE3 LIPF EPS8L1 PKHD1L1 ANXA9 MYRF CRB2	2.34e-06	179	148	7	f5f3945ef3b9efc5921a71fd51deeb2c80f0ce11
ToppCell	facs-Liver-Hepatocytes-24m-Epithelial\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDHR5 ACAD10 MIA2 CES3 MYRF GASK1A PROX1	2.61e-06	182	148	7	770ce9f3f4538d0181a0181543841bc964c68274
ToppCell	facs-Liver-Hepatocytes-24m-Epithelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDHR5 ACAD10 MIA2 CES3 MYRF GASK1A PROX1	2.61e-06	182	148	7	77ab860e2add49dad0c1ffbfc64278ad499dfbd5
ToppCell	facs-Liver-Hepatocytes-24m-Epithelial-hepatocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDHR5 ACAD10 MIA2 CES3 MYRF GASK1A PROX1	2.61e-06	182	148	7	4921c7d5687cc79f896b39753bb621d7e3d2972f
ToppCell	facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l20-23\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TNIK PPAN ANK3 RTN2 TLN2 DMD PROX1	3.12e-06	187	148	7	69b47f00598d647e2a99427ebddf42c339428e47
ToppCell	Control-Fibroblasts-Other_FB\|Control / group, cell type (main and fine annotations)	DPYSL3 ABI3BP FAT3 ANTXR1 TLN2 DMD MMP16	3.12e-06	187	148	7	bd3739c4a52aa1ba5deffd778e113a9800f7e158
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_mesothelial_(19)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	ANK3 EPS8L1 PKHD1L1 SEMA3B MYRF GASK1A CRB2	3.59e-06	191	148	7	4c4eb61e6179d2f8fc524d2f813db9cba84f67a2
ToppCell	COVID-19-Fibroblasts-Other_FB\|COVID-19 / group, cell type (main and fine annotations)	DPYSL3 ABI3BP MAGI2 PTPRK ANTXR1 TLN2 DMD	3.85e-06	193	148	7	e6b75be08e33c1de079fb5c02f0b4468128b369c
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DPYSL3 ANK2 ABI3BP HMCN2 ANTXR1 TLN2 MMP16	3.98e-06	194	148	7	439d3f17c1f4736122b330e98add9292c7036a8e
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK2 ABI3BP FAT3 MAGI2 LRP1 ANTXR1 DMD	3.98e-06	194	148	7	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DPYSL3 ANK2 ABI3BP HMCN2 ANTXR1 TLN2 MMP16	4.12e-06	195	148	7	ff0aa455e9844a6d7ae57ff59fb6cea825cf1fc2
ToppCell	facs-Thymus-Thymus_Epithelium\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DPYSL3 ANK2 ABI3BP RAB34 LRP1 ANTXR1 DMD	4.26e-06	196	148	7	6bc1187dfc4860a4e09032d7ea87ba3d9fe9f363
ToppCell	facs-Thymus-Thymus_Epithelium-18m\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DPYSL3 ANK2 ABI3BP RAB34 LRP1 ANTXR1 DMD	4.26e-06	196	148	7	c8c89e469402e11aa2a9561e859b6fd1fb66c39b
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SCHIP1 ANK2 CELSR2 PTPRK SORCS2 MYRF PROX1	4.70e-06	199	148	7	5d2e85e40b6b52b1809e680b952913d77215b3d0
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SCHIP1 ANK2 CELSR2 PTPRK SORCS2 MYRF PROX1	4.70e-06	199	148	7	9dd4b17fb8c70ab9e126b23b72600463f3db832d
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-Z\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SCHIP1 ANK2 CELSR2 PTPRK SORCS2 MYRF PROX1	4.70e-06	199	148	7	6fb5f931e6217142de38c1fffc011e63bda4772b
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SCHIP1 ANK2 CELSR2 PTPRK SORCS2 MYRF PROX1	4.70e-06	199	148	7	1bb5797e8e0552bf9b44bf4c958d1aa6dbe6c756
ToppCell	COVID-19_Mild\|World / 5 Neutrophil clusters in COVID-19 patients	ANK3 ACO1 USF3 IGF2R MARF1 FAM157B	1.20e-05	152	148	6	2ff0980dfd8d430cca14649151d856edef115720
ToppCell	3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Progenitor\|lymph-node_spleen / Manually curated celltypes from each tissue	SCHIP1 RAMP3 FAT3 TRIM71 ZNF711 DNMT3B	2.04e-05	167	148	6	cb396f3edb9e8fdc316091e8e193dbba50e0be0c
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell_prolif\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	RAMP3 PKHD1L1 NHSL1 ARHGAP31 DISP3 TBCD	2.41e-05	172	148	6	c056d44e2e130ceccadfcdceb192a7f095d779c8
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 DRAM1 PCP2 EPS8L1 SEMA3B BEX4	2.49e-05	173	148	6	45808cf69122c16b9d2b5ffa06d15392c55954b7
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2-AT1/AT2_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 DRAM1 PCP2 EPS8L1 SEMA3B BEX4	2.49e-05	173	148	6	7fa9dbcb258c3ab974490063951620e2def03db1
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NR4A2 CPNE5 PPP1R1A PTPRK MMP16 CPVL	2.57e-05	174	148	6	bc978a2148a0261a4f9d1ca5479b707e224566be
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar-Macro_c3-EREG\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	TNIK PPAN SH2B3 TEFM FAM13A TBCD	2.57e-05	174	148	6	feed99acd868db61f045e666dbfdcaed91ca1488
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_B-B_cell-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	UPB1 PKHD1L1 RTN2 ZNF711 CNTNAP2 MARF1	2.65e-05	175	148	6	69ed3c7c45df6bef70f5f2ff003531160bf3b32b
ToppCell	(0)_Normal/No_Treatment-(3)_LEPR+_perivascular_cells\|World / Stress and Cell class	DPYSL3 ANK3 FAM13A LRP1 ANTXR1 TLN2	2.74e-05	176	148	6	ce2c32b5ce0da848eb4da35ce4d215cdf74d9113
ToppCell	mild_COVID-19_(asymptomatic)-B_memory\|World / disease group, cell group and cell class (v2)	ANK3 PCDHB14 CPNE5 CNTNAP2 LY9 UVRAG	2.83e-05	177	148	6	057871e211c6508b2a679d391f3cf0ac7ccfc628
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ANK3 TRIM71 GRHL2 PTPRK SORCS2 DMD	3.01e-05	179	148	6	815b959ce8721c5ded70c0ca6e318dafc691746e
ToppCell	droplet-Lung-LUNG-30m-Epithelial-type_II_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ANK3 DRAM1 CDHR5 PPP1R1A BEX4 CDH16	3.20e-05	181	148	6	cadb18fc73031eb9f779599e15cd7861337fee78
ToppCell	droplet-Lung-LUNG-30m-Epithelial-Alveolar_Epithelial_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ANK3 DRAM1 CDHR5 PPP1R1A BEX4 CDH16	3.20e-05	181	148	6	85bec4d3f255f4c61c790325eeb50ad38f709ef2
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ABI3BP FAT3 MAGI2 LRP1 DMD GASK1A	3.41e-05	183	148	6	7eae9b3b4d1c9b135fa7cff348393d4adec474b4
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TNIK ANK3 DRAM1 GRHL2 PTPRK SORCS2	3.41e-05	183	148	6	6847c1252d6bb105524f812658112517fd351eab
ToppCell	facs-Liver-Hepatocytes-24m\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACO1 CDHR5 ACAD10 MIA2 CES3 GASK1A	3.41e-05	183	148	6	d0721c6aa426953a520d40e976b6e65aa7ca65e8
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NR4A2 CPNE5 PPP1R1A PTPRK MMP16 CPVL	3.41e-05	183	148	6	01ad18f198195ce341bae01a1c8c253cc4607766
ToppCell	wk_08-11-Hematologic_Lymphocytic-NK-Cycling_NK\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	KLHDC7B ITGAD ADAM8 ITGB2 LY9 ANXA9	3.41e-05	183	148	6	19652ca16989cb0be7d444cb5bf209b32d163bdb
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FAT3 PKHD1L1 GUCY2F DISP3 TLN2 DMD	3.51e-05	184	148	6	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	wk_20-22-Mesenchymal-Mesothelial\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	SERPINE3 EPS8L1 PKHD1L1 ANXA9 MYRF CRB2	3.51e-05	184	148	6	804f8a41cd6b1361448872bf352bf0a38a0fac66
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FAT3 PKHD1L1 GUCY2F DISP3 TLN2 DMD	3.51e-05	184	148	6	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FAT3 PKHD1L1 GUCY2F DISP3 TLN2 DMD	3.51e-05	184	148	6	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	wk_20-22-Mesenchymal-Mesothelial-Late_mesothelial\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	SERPINE3 EPS8L1 PKHD1L1 ANXA9 MYRF CRB2	3.51e-05	184	148	6	60dd055c2e2e92b838ac649c12e8cccd9c3b1b71
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 ABI3BP MAGI2 ANTXR1 HFM1 DMD	3.62e-05	185	148	6	6712512100ccef456d2e2bd201d0987986c92ac9
ToppCell	COVID-19-Fibroblasts-Adventitial_FB\|COVID-19 / group, cell type (main and fine annotations)	DPYSL3 ANK2 ABI3BP MAGI2 TLN2 GASK1A	3.62e-05	185	148	6	a5aebf2b9b05b550d021272731d68af9a6b1229d
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 ABI3BP MAGI2 LRP1 ANTXR1 DMD	3.62e-05	185	148	6	3b2dfc8f4c87be516265dbecfc251276034d0efd
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-mesothelial_cell-Mesothelium_(RGS5+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SERPINE3 ANK3 EPS8L1 DMD MYRF CRB2	3.62e-05	185	148	6	11fbea1eb1d9a3e4480d0d2b0f7b02e2866b8142
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ANK3 TRIM71 GRHL2 PTPRK SORCS2 DMD	3.73e-05	186	148	6	2ea5ff14861e5f91d0e6a5767c403a24045d715c
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DRAM1 TRIM71 GRHL2 FAM13A SEMA3B MYRF	3.73e-05	186	148	6	4e94158db52df41d71e67b02b9895a358eebee0f
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PCP2 TRIM71 GRHL2 SEMA3B SORCS2 MYRF	3.84e-05	187	148	6	58d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCell	-Unknown-Endothelial-Myofibroblast\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 ABI3BP USP24 MAGI2 ARHGAP31 GASK1A	3.96e-05	188	148	6	6468fa95ad0395395301115286f2d8c0df5d3882
ToppCell	-Unknown-Endothelial\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 ABI3BP USP24 MAGI2 ARHGAP31 GASK1A	3.96e-05	188	148	6	7a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6
ToppCell	-Unknown\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK3 ABI3BP USP24 MAGI2 ARHGAP31 GASK1A	3.96e-05	188	148	6	9cb718bfe1358c6fd842f096e228eb0abb9aefc6
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DPYSL3 ABI3BP HMCN2 LRP1 ANTXR1 DMD	3.96e-05	188	148	6	ce85a56ac27a6432421dde93a1bafa8b943244b9
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-7\|TCGA-Colorectal / Sample_Type by Project: Shred V9	DPYSL3 CCDC8 DIDO1 IGF2R ANTXR1 PROX1	3.96e-05	188	148	6	14bc73cf79c79c9f208369fd8d498e5b26e0114d
ToppCell	Control-Fibroblasts-Adventitial_FB\|Control / group, cell type (main and fine annotations)	DPYSL3 ANK2 ABI3BP LRP1 TLN2 GASK1A	3.96e-05	188	148	6	706a26c372add839d947749f0521a0e1f5c9b0ec
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ABI3BP FAT3 MAGI2 LRP1 DMD GASK1A	4.08e-05	189	148	6	45e588b2a4ad9e3ff74e22d9d627ed3571f3b8b8
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ANK3 DRAM1 GRHL2 NHSL1 PTPRK SORCS2	4.20e-05	190	148	6	8aea807a2bcf0b653b4de6202b6ecb0f0683cc2e
ToppCell	facs-Thymus-Flowthrough-24m-Mesenchymal-fibroblast\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABI3BP NR4A2 RAB34 LRP1 ANTXR1 MMP16	4.20e-05	190	148	6	990ac07f4b0a22041daac7502f74fafd6d258cba
ToppCell	Adult-Mesenchymal-matrix_fibroblast_2_cell-D175\|Adult / Lineage, Cell type, age group and donor	DPYSL3 ANK2 ABI3BP ANTXR1 MMP16 GASK1A	4.20e-05	190	148	6	7dcca3469f3a3b70db0420cb94f7765f39492f06
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DPYSL3 ABI3BP HMCN2 LRP1 ANTXR1 DMD	4.20e-05	190	148	6	efb757f11c2809e66ddb48a5c84f5433f111cb7c
ToppCell	(1)_Control_(PBS)-(3)_LEPR+_perivascular_cells\|World / Stress and Cell class	DPYSL3 RAB34 FAM13A LRP1 ANTXR1 TLN2	4.20e-05	190	148	6	ec0ab31266583a0966ac7615d5c0fabb7b7e66e8
ToppCell	facs-Thymus-Flowthrough-24m-Mesenchymal-fibroblast\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABI3BP NR4A2 RAB34 LRP1 ANTXR1 MMP16	4.20e-05	190	148	6	fc9bbe5e6e0ec3cfa47bf479d8b09a0fc53169cc
ToppCell	facs-Thymus-Flowthrough-24m-Mesenchymal\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABI3BP NR4A2 RAB34 LRP1 ANTXR1 MMP16	4.20e-05	190	148	6	39ecdf8815e235771132684dfc1aff1917e20965
ToppCell	5'-GW_trimst-2-SmallIntestine-Mesenchymal-mesothelial_cell\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SERPINE3 EPS8L1 PKHD1L1 ANXA9 MYRF CRB2	4.32e-05	191	148	6	5343a527de6b0f852f45020a91f5b4869e78f13a
ToppCell	wk_15-18-Mesenchymal-Mesothelial\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	SERPINE3 EPS8L1 PKHD1L1 ANXA9 MYRF CRB2	4.32e-05	191	148	6	b5374674312ff5803a1d369f5533027532344679
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TNIK ANK3 DRAM1 GRHL2 PTPRK SORCS2	4.32e-05	191	148	6	a0332a4ef629510fb313ec119195c44a3f704a80
ToppCell	Control-Stromal_mesenchymal\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ABI3BP FAT3 MAGI2 LRP1 DMD GASK1A	4.32e-05	191	148	6	14057205ddb9b4bbc582d1358d13cf36d979a61b
ToppCell	5'-GW_trimst-2-SmallIntestine-Mesenchymal-mesothelial_cell-Mesothelium\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SERPINE3 EPS8L1 PKHD1L1 ANXA9 MYRF CRB2	4.32e-05	191	148	6	a25a5f9a380031fdaf57677a079f97a90f0550c0
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ANK3 TRIM71 GRHL2 NHSL1 PTPRK MYRF	4.32e-05	191	148	6	ca5669bd6f4a17471acae3eb229f845cc2e08efa
ToppCell	(0)_Normal/No_Treatment-(3)_LEPR+_perivascular_cells\|(0)_Normal/No_Treatment / Stress and Cell class	DPYSL3 RAB34 FAM13A LRP1 ANTXR1 TLN2	4.45e-05	192	148	6	7a2ad0bdae647b88e799e62767605f2f3c5a426f
ToppCell	LPS_only-Stromal_mesenchymal\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK2 ABI3BP FAT3 MAGI2 LRP1 ANTXR1	4.45e-05	192	148	6	162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK2 ABI3BP FAT3 MAGI2 LRP1 ANTXR1	4.45e-05	192	148	6	3d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell	Mesenchymal-matrix_fibroblast_2_cell\|World / Lineage, Cell type, age group and donor	DPYSL3 ANK2 ABI3BP ANTXR1 TLN2 MMP16	4.45e-05	192	148	6	a769158c49d2b208c4224d85e7ae68c85cc372ed
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK2 ABI3BP FAT3 MAGI2 LRP1 ANTXR1	4.45e-05	192	148	6	deeecd26972241846b4cb998edf0c7a87ff0c4df
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6\|TCGA-Prostate / Sample_Type by Project: Shred V9	USF3 IGF2R USP38 PTPRK SBF2 PUM1	4.58e-05	193	148	6	abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK2 ABI3BP FAT3 MAGI2 LRP1 ANTXR1	4.58e-05	193	148	6	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DPYSL3 ANK2 ABI3BP ANTXR1 TLN2 MMP16	4.58e-05	193	148	6	9ab47b360bee1d4f1092c2269e58acebe9584021
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro-stroma-endosteal_fibroblast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	RAMP3 ANK3 ABI3BP PPP1R1A CSPG4 LRP1	4.72e-05	194	148	6	69362e13158033de44f90f3773db6c0f27de8cb3
ToppCell	(5)_Fibroblasts-(5)_Fibroblast-J_(Lipofibroblast)\|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4)	ANK2 NR4A2 MCL1 CPNE5 MYRF CRB2	4.72e-05	194	148	6	784b15119c91ace33d34bfb3d68c182566a3e9a8
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK2 ABI3BP FAT3 MAGI2 LRP1 ANTXR1	4.72e-05	194	148	6	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ANK2 ABI3BP FAT3 MAGI2 LRP1 ANTXR1	4.72e-05	194	148	6	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	10x3'2.3-week_17-19-Mesenchymal_osteo-stroma-osteoblast_precursor\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	CCDC8 FAT3 CNTNAP2 LRP1 ANTXR1 MMP16	4.85e-05	195	148	6	ec12cfb2fce44cc2de4e198ef5af075e626f0329
ToppCell	Control-Classical_Monocyte-cMono_2\|Control / Disease condition and Cell class	MYH9 NR4A2 MCL1 ITGB2 LRP1 CPVL	4.85e-05	195	148	6	0fea64ee3eedf3929abb0dd9c5f5fc72f181eed9
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DPYSL3 FAT3 HMCN2 ANTXR1 DMD MMP16	4.99e-05	196	148	6	1522958a92e0126326a9f0d9fb1c5b5c50b001ea
ToppCell	10x3'2.3-week_14-16-Mesenchymal_fibro\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	DPYSL3 RAMP3 ANK2 ABI3BP PPP1R1A ANTXR1	4.99e-05	196	148	6	ee45e4de9d706ec87094e87f47d3e514539b8092
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	TNIK ABI3BP FAT3 SBF2 CNTNAP2 LRP1	4.99e-05	196	148	6	1450cb69c5bf469e97c03bf1890f6f7c54165b8a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DPYSL3 FAT3 HMCN2 ANTXR1 DMD MMP16	4.99e-05	196	148	6	1c8294014713684b50885e638668f2ce75f357f0
ToppCell	10x3'2.3-week_14-16-Mesenchymal_fibro-stroma\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	DPYSL3 RAMP3 ANK2 ABI3BP PPP1R1A ANTXR1	4.99e-05	196	148	6	fa4a85a3cd52df0da5dfedc0e584e9df8c61ce89
ToppCell	Parenchymal-10x5prime-Stromal-Mesofibroblastic\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	ABI3BP PKHD1L1 SEMA3B ANXA9 MYRF CRB2	5.14e-05	197	148	6	88a86286b9c3ea3b076d7464faec42d0392ee7f8
ToppCell	Parenchymal-10x5prime-Stromal-Mesofibroblastic-Mesothelia\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	ABI3BP PKHD1L1 SEMA3B ANXA9 MYRF CRB2	5.14e-05	197	148	6	2773d2eb5f232a7e49da116efffcb6bf5eb90810
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Neuronal-midbrain/hindbrain_cells\|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.	DPYSL3 ANK2 ANK3 EPS8L1 RTN2 PPP1R1A	5.14e-05	197	148	6	c7078f6fcf27319ba8c5ebe700bcae7f1e7e39c1
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-memory_B_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CPNE5 PKHD1L1 ZNF711 PTPRK LY9 UVRAG	5.14e-05	197	148	6	43e576bd6997915d21137e233e36984eba31f637
ToppCell	Biopsy_Other_PF-Mesenchymal-Mesothelial_cells\|Biopsy_Other_PF / Sample group, Lineage and Cell type	ABI3BP PKHD1L1 SEMA3B ANXA9 MYRF CRB2	5.28e-05	198	148	6	86736f01e61bf4961f060b24ee1f1f48340737dd
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	TNIK ABI3BP FAT3 CNTNAP2 LRP1 ANTXR1	5.28e-05	198	148	6	17dc055e2a289496d9c5cdbf3297bdf906dc6d22
Drug	Spaglumic acid [4910-46-7]; Down 200; 13.2uM; HL60; HT_HG-U133A	TNIK TRIOBP PIDD1 EPS8L1 ADAM8 CES2 BPGM FAM13A CES3 TAB1	5.44e-07	195	146	10	2962_DN
Drug	Disulfiram [97-77-8]; Down 200; 13.4uM; PC3; HT_HG-U133A	TNIK TRIOBP PIDD1 MFAP3L ZSCAN32 USP5 FAM13A TLN2 MYRF TBCD	6.26e-07	198	146	10	5729_DN
Drug	Resveratrol [501-36-0]; Down 200; 17.6uM; MCF7; HT_HG-U133A	NR4A2 DIDO1 AP3B1 CES2 STK11 USP5 GMEB1 CES3 OTUD4	4.28e-06	192	146	9	5509_DN
Drug	Pancuronium bromide [15500-66-0]; Down 200; 5.4uM; PC3; HT_HG-U133A	MFHAS1 NR4A2 EPS8L1 STK11 FAM13A CELSR2 CES3 LRP1 PROX1	5.06e-06	196	146	9	4570_DN
Drug	Nortriptyline hydrochloride [894-71-3]; Up 200; 13.4uM; PC3; HT_HG-U133A	MFHAS1 EPS8L1 ADAM8 ITGB2 USP5 CELSR2 LRP1 TLN2 MYRF	5.06e-06	196	146	9	7300_UP
Drug	Sulfamonomethoxine [1220-83-3]; Up 200; 14.2uM; PC3; HT_HG-U133A	DPYSL3 RRP1B RTN2 CES2 USP5 MIA2 TAF5L ATP2B3 SOS1	5.27e-06	197	146	9	5843_UP
Drug	Pyrithyldione [77-04-3]; Up 200; 24uM; PC3; HT_HG-U133A	NPR2 TRIOBP MCL1 ITGB2 MFAP3L ZNF711 CNTNAP2 TLN2 TRAPPC14	5.27e-06	197	146	9	7153_UP
Drug	Canrenoic acid potassium salt [2181-04-6]; Up 200; 10uM; PC3; HT_HG-U133A	ANK3 EPS8L1 MFAP3L USP5 CELSR2 LRP1 TLN2 MYRF ZNF574	5.49e-06	198	146	9	2065_UP
Drug	Cefotaxime sodium salt [64485-93-4]; Up 200; 8.4uM; PC3; HT_HG-U133A	NR4A2 RTN2 CES2 MFAP3L GMEB1 CES3 OTUD4 TLN2 SOS1	5.96e-06	200	146	9	5830_UP
Drug	0179445-0000 [211246-22-9]; Down 200; 1uM; MCF7; HT_HG-U133A	MDM1 EPS8L1 RTN2 MFAP3L ZSCAN32 CNTNAP2 CES3 LY9	3.72e-05	194	146	8	4758_DN
Drug	Moricizine hydrochloride [31883-05-3]; Up 200; 8.6uM; HL60; HT_HG-U133A	RRP1B UBR4 NR4A2 MCL1 EPS8L1 STK11 FAM13A TLN2	3.72e-05	194	146	8	2959_UP
Drug	Dicyclomine hydrochloride [67-92-5]; Down 200; 11.6uM; PC3; HT_HG-U133A	TNIK ANK3 CES2 FAM13A CELSR2 MMP16 ZNF574 PROX1	3.86e-05	195	146	8	4581_DN
Drug	Sulfaphenazole [526-08-9]; Down 200; 12.8uM; PC3; HT_HG-U133A	RPS6KA4 RRP1B ITGB2 CES2 BPGM MIA2 TRAPPC14 ZNF574	4.00e-05	196	146	8	1794_DN
Drug	2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A	CAD RPS6KA4 ANK3 TRIOBP ACAD10 USP5 TRAPPC14 ZNF574	4.14e-05	197	146	8	1634_DN
Drug	Bephenium hydroxynaphthoate [3818-50-6]; Down 200; 9uM; MCF7; HT_HG-U133A	NPR2 EPS8L1 MFAP3L ZSCAN32 USP5 SEMA3B TRAPPC14 PUM1	4.14e-05	197	146	8	6466_DN
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; HL60; HT_HG-U133A	RPS6KA4 MFHAS1 NR4A2 MCL1 EPS8L1 ADAM8 ZSCAN32 TBCD	4.14e-05	197	146	8	2171_DN
Drug	Succinylsulfathiazole [116-43-8]; Down 200; 11.2uM; PC3; HT_HG-U133A	ANK3 RRP1B NR4A2 MIA2 CNTNAP2 GMEB1 TLN2 TBCD	4.14e-05	197	146	8	4265_DN
Drug	Myricetin [529-44-2]; Down 200; 12.6uM; PC3; HT_HG-U133A	NPR2 MFHAS1 DIDO1 ZSCAN32 FAM13A SEMA3B GMEB1 TLN2	4.30e-05	198	146	8	4090_DN
Drug	Quinic acid [86-68-0]; Down 200; 19.6uM; MCF7; HT_HG-U133A	NPR2 PIDD1 DIDO1 EPS8L1 RTN2 CES2 MFAP3L CNTNAP2	4.30e-05	198	146	8	6019_DN
Drug	Naproxen [22204-53-1]; Up 200; 17.4uM; PC3; HT_HG-U133A	NPR2 NR4A2 PIDD1 MFAP3L FAM13A SEMA3B TBCD PROX1	4.30e-05	198	146	8	6358_UP
Drug	haloperidol; Down 200; 10uM; PC3; HT_HG-U133A	RPS6KA4 RRP1B B3GAT3 ZSCAN32 CELSR2 CNTNAP2 TBCD ZNF574	4.30e-05	198	146	8	1244_DN
Drug	Paromomycin sulfate [1263-89-4]; Up 200; 5.6uM; HL60; HT_HG-U133A	TNIK STK11 CSPG4 TLN2 HTR3B TRAPPC14 MMP16 MYRF	4.30e-05	198	146	8	3017_UP
Drug	Nitrofurantoin [67-20-9]; Up 200; 16.8uM; PC3; HT_HG-U133A	TNIK RRP1B MFHAS1 NR4A2 ACAD10 SEMA3B CNTNAP2 TBCD	4.30e-05	198	146	8	7373_UP
Drug	Ciprofibrate [52214-84-3]; Down 200; 13.8uM; PC3; HT_HG-U133A	MFHAS1 NR4A2 MFAP3L MIA2 TLN2 TRAPPC14 MYRF TBCD	4.45e-05	199	146	8	5740_DN
Drug	Fosfosal [6064-83-1]; Up 200; 18.4uM; MCF7; HT_HG-U133A	NPR2 MAN2A2 MCL1 RTN2 MFAP3L CNTNAP2 CES3 OTUD4	4.45e-05	199	146	8	4823_UP
Drug	Pergolide mesylate [66104-23-2]; Down 200; 9.8uM; PC3; HT_HG-U133A	NPR2 RPS6KA4 TNRC6B EPS8L1 RTN2 CES2 TAB1 SOS1	4.45e-05	199	146	8	7271_DN
Drug	DNA-PK Inhibitor III; Down 200; 1uM; PC3; HT_HG-U133A	NPR2 RRP1B MFHAS1 STK11 MIA2 CNTNAP2 GMEB1 OTUD4	4.45e-05	199	146	8	7518_DN
Drug	valdecoxib; Up 200; 10uM; PC3; HT_HG-U133A	NPR2 MAN2A2 NR4A2 ADAM8 B3GAT3 MFAP3L CAPN10 LRP1	4.61e-05	200	146	8	6408_UP
Drug	Picotamide monohydrate [80530-63-8]; Up 200; 10.2uM; PC3; HT_HG-U133A	NPR2 PIDD1 EPS8L1 CNTNAP2 CES3 TLN2 MMP16 MYRF	4.61e-05	200	146	8	2070_UP
Drug	Tribenoside [10310-32-4]; Up 200; 8.4uM; HL60; HT_HG-U133A	TNIK DPYSL3 NR4A2 TRIOBP CAPN10 MIA2 FAM13A	1.89e-04	184	146	7	2946_UP
Drug	geldanamycin; Up 200; 1uM; PC3; HT_HG-U133A	ABI3BP MDM1 NR4A2 DIDO1 SEMA3B TRAPPC14 MMP16	2.02e-04	186	146	7	1228_UP
Drug	Monensin sodium salt [22373-78-0]; Down 200; 5.8uM; PC3; HT_HG-U133A	ANK3 NR4A2 MCL1 STK11 USP5 TRAPPC14 MYRF	2.09e-04	187	146	7	7402_DN
Drug	GSK-3beta Inhibitor VIII; Down 200; 10uM; PC3; HT_HG-U133A	TNIK NPR2 ABI3BP CES2 SLC38A10 BPGM ZNF574	2.16e-04	188	146	7	7097_DN
Drug	Eburnamonine (-) [4880-88-0]; Down 200; 13.6uM; PC3; HT_HG-U133A	TNIK PIDD1 DIDO1 GRHL2 ZSCAN32 IGF2R MMP16	2.31e-04	190	146	7	7154_DN
Drug	RPR 121056	CES2 CES3	2.43e-04	4	146	2	ctd:C100720
Drug	GW8510; Up 200; 10uM; MCF7; HT_HG-U133A	NPR2 TRIOBP ACAD10 ADAM8 USP5 SEMA3B TLN2	2.46e-04	192	146	7	7062_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A	NPR2 NR4A2 PIDD1 EPS8L1 ADAM8 CES3 TBCD	2.46e-04	192	146	7	2450_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A	NR4A2 PIDD1 USP5 CSPG4 GMEB1 OTUD4 TAB1	2.54e-04	193	146	7	3077_DN
Drug	Halcinonide [3093-35-4]; Up 200; 8.8uM; PC3; HT_HG-U133A	TNIK TRIOBP MFAP3L GMEB1 CES3 TLN2 TBCD	2.62e-04	194	146	7	7379_UP
Drug	2-Chloropyrazine [14508-49-7]; Down 200; 35uM; MCF7; HT_HG-U133A	ABI3BP TRIOBP PIDD1 ACAD10 EPS8L1 CAPN10 TAB1	2.62e-04	194	146	7	3570_DN
Drug	bromfenacoum	TNIK DPYSL3 MYH9 AFTPH ANK3 PCP2 TNRC6B DIDO1 TXNRD1 NHSL1 USP5 SORCS2 LRP1	2.67e-04	644	146	13	ctd:C013418
Drug	troglitazone; Down 200; 10uM; MCF7; HT_HG-U133A	NPR2 RRP1B TNRC6B ACAD10 EPS8L1 TRAPPC14 SOS1	2.70e-04	195	146	7	1657_DN
Drug	AH23848 hemicalcium salt hydrate; Up 200; 1uM; MCF7; HT_HG-U133A	MDM1 ADAM8 STK11 MIA2 CELSR2 ZNF468 TRAPPC14	2.70e-04	195	146	7	6903_UP
Drug	Gabexate mesilate [56974-61-9]; Down 200; 9.6uM; PC3; HT_HG-U133A	DPYSL3 ANK3 MFAP3L ZNF711 MIA2 GMEB1 TBCD	2.70e-04	195	146	7	4220_DN
Drug	Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; PC3; HT_HG-U133A	MDM1 USP5 BEX4 MMP16 MYRF TBCD SOS1	2.70e-04	195	146	7	7385_DN
Drug	Mefexamide hydrochloride [3413-64-7]; Up 200; 12.6uM; PC3; HT_HG-U133A	DPYSL3 ABI3BP NR4A2 STK11 TAB1 TAF5L DNMT3B	2.70e-04	195	146	7	2121_UP
Drug	Benzocaine [94-09-7]; Down 200; 24.2uM; PC3; HT_HG-U133A	RRP1B MFHAS1 TRIOBP MCL1 MFAP3L GMEB1 TBCD	2.70e-04	195	146	7	4224_DN
Drug	Gentamicine sulfate [1405-41-0]; Up 200; 2.6uM; MCF7; HT_HG-U133A	ADAM8 CAPN10 PPP1R1A ZSCAN32 TLN2 MMP16 PROX1	2.70e-04	195	146	7	7237_UP
Drug	Papaverine hydrochloride [61-25-6]; Up 200; 10.6uM; MCF7; HT_HG-U133A	PIDD1 EPS8L1 ADAM8 CELSR2 SEMA3B GMEB1 TRAPPC14	2.70e-04	195	146	7	6245_UP
Drug	Cyclopenthiazide [742-20-1]; Down 200; 10.6uM; PC3; HT_HG-U133A	TNIK RRP1B NR4A2 RTN2 USP5 GMEB1 TBCD	2.70e-04	195	146	7	4229_DN
Drug	Hesperetin [520-33-2]; Up 200; 13.2uM; MCF7; HT_HG-U133A	MAN2A2 TNRC6B STK11 SEMA3B CNTNAP2 CES3 TRAPPC14	2.79e-04	196	146	7	5350_UP
Drug	Labetalol hydrochloride [32780-64-6]; Down 200; 11uM; PC3; HT_HG-U133A	PIDD1 CNTNAP2 CES3 TLN2 MYRF TBCD ZNF574	2.79e-04	196	146	7	4473_DN
Drug	Lynestrenol [52-76-6]; Up 200; 14uM; PC3; HT_HG-U133A	NR4A2 MCL1 MFAP3L PPP1R1A LY9 KLK2 TBCD	2.79e-04	196	146	7	6756_UP
Drug	Dobutamine hydrochloride [49745-95-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	MCL1 ACAD10 MFAP3L MIA2 ANTXR1 TBCD ZNF574	2.79e-04	196	146	7	3206_DN
Drug	Sulfadoxine [2447-57-6]; Up 200; 12.8uM; PC3; HT_HG-U133A	MDM1 RTN2 MFAP3L USP5 MIA2 CELSR2 CNTNAP2	2.79e-04	196	146	7	5852_UP
Drug	Parbendazole [14255-87-9]; Up 200; 16.2uM; PC3; HT_HG-U133A	TNIK MCL1 CAPN10 FAM13A CNTNAP2 TLN2 PROX1	2.79e-04	196	146	7	4535_UP
Drug	Oxybenzone [131-57-7]; Down 200; 17.6uM; PC3; HT_HG-U133A	MAN2A2 NR4A2 EPS8L1 ADAM8 ITGB2 FAM13A TRAPPC14	2.79e-04	196	146	7	6309_DN
Drug	Pinacidil [85371-64-8]; Down 200; 16.4uM; HL60; HT_HG-U133A	NR4A2 TRIOBP EPS8L1 ADAM8 RTN2 CELSR2 TAB1	2.79e-04	196	146	7	2406_DN
Drug	Acetazolamide [59-66-5]; Down 200; 18uM; MCF7; HT_HG-U133A	NPR2 USP24 ACAD10 MIA2 SEMA3B TLN2 BEX4	2.79e-04	196	146	7	1686_DN
Drug	Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Up 200; 5.8uM; PC3; HT_HG-U133A	NR4A2 MFAP3L CAPN10 MAGI2 BMP8B MMP16 PROX1	2.79e-04	196	146	7	4508_UP
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; MCF7; HT_HG-U133A	SH2B3 MDM1 NR4A2 PIDD1 CLSTN1 ADAM8 B3GAT3	2.79e-04	196	146	7	3429_DN
Drug	Clioquinol [130-26-7]; Down 200; 13uM; PC3; HT_HG-U133A	RRP1B DIDO1 ITGB2 CES2 USP5 CNTNAP2 TLN2	2.79e-04	196	146	7	4663_DN
Drug	Mebeverine hydrochloride [2753-45-9]; Down 200; 8.6uM; PC3; HT_HG-U133A	RPS6KA4 ANK3 RRP1B MCL1 USP5 ANTXR1 TAB1	2.79e-04	196	146	7	7147_DN
Drug	Tetracycline hydrochloride [64-75-5]; Up 200; 8.4uM; PC3; HT_HG-U133A	ANK3 ABI3BP MCL1 ACAD10 EPS8L1 MFAP3L TLN2	2.79e-04	196	146	7	2080_UP
Drug	Methazolamide [554-57-4]; Down 200; 17uM; HL60; HT_HG-U133A	RRP1B MCL1 USP5 MIA2 CELSR2 OTUD4 TBCD	2.79e-04	196	146	7	2733_DN
Drug	Mesalamine [89-57-6]; Down 200; 26.2uM; MCF7; HT_HG-U133A	NPR2 RPS6KA4 NR4A2 PIDD1 ADAM8 MFAP3L MMP16	2.87e-04	197	146	7	3584_DN
Drug	Citalopram hydrobromide [59729-32-7]; Up 200; 1uM; PC3; HT_HG-U133A	TNIK MAN2A2 CES2 MAGI2 LRP1 TLN2 MMP16	2.87e-04	197	146	7	4555_UP
Drug	(+,-)-Synephrine [94-07-5]; Up 200; 24uM; PC3; HT_HG-U133A	ADAM8 MFAP3L STK11 FAM13A CNTNAP2 TRAPPC14 MYRF	2.87e-04	197	146	7	7150_UP
Drug	Clonidine hydrochloride [4205-91-8]; Up 200; 15uM; PC3; HT_HG-U133A	ANK2 MFAP3L ZNF711 ZSCAN32 LRP1 TLN2 PROX1	2.87e-04	197	146	7	4478_UP
Drug	Pindolol [13523-86-9]; Up 200; 16.2uM; PC3; HT_HG-U133A	NR4A2 PIDD1 USP5 FAM13A LRP1 TLN2 MYRF	2.87e-04	197	146	7	2075_UP
Drug	Metronidazole [443-48-1]; Down 200; 23.4uM; HL60; HG-U133A	PIDD1 TNRC6B TEFM USP5 IGF2R TRAPPC14 TBCD	2.87e-04	197	146	7	2003_DN
Drug	Minoxidil [38304-91-5]; Up 200; 19.2uM; MCF7; HT_HG-U133A	USP24 PIDD1 MFAP3L BMP8B TAF5L TRAPPC14 MMP16	2.87e-04	197	146	7	1496_UP
Drug	Phenformin hydrochloride [834-28-6]; Down 200; 16.6uM; HL60; HT_HG-U133A	NR4A2 ACAD10 ADAM8 RTN2 USP5 GMEB1 TRAPPC14	2.87e-04	197	146	7	2350_DN
Drug	Boldine [476-70-0]; Down 200; 12.2uM; MCF7; HT_HG-U133A	RPS6KA4 EPS8L1 B3GAT3 PCF11 BPGM BEX4 TRAPPC14	2.87e-04	197	146	7	2804_DN
Drug	Amiloride hydrochloride dihydrate [17440-83-4]; Down 200; 13.2uM; MCF7; HT_HG-U133A	ACAD10 CES2 MIA2 SEMA3B GMEB1 TLN2 TRAPPC14	2.87e-04	197	146	7	1470_DN
Drug	Nefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; PC3; HT_HG-U133A	NPR2 PIDD1 FAM13A CES3 TLN2 MMP16 ZNF574	2.96e-04	198	146	7	3730_DN
Drug	Quinethazone [73-49-4]; Up 200; 13.8uM; PC3; HT_HG-U133A	NR4A2 MFAP3L CAPN10 FAM13A CES3 LRP1 TLN2	2.96e-04	198	146	7	4529_UP
Drug	Azathioprine [446-86-6]; Up 200; 14.4uM; PC3; HG-U133A	DPYSL3 USP24 EPS8L1 USP5 RNF167 SLC38A10 TLN2	2.96e-04	198	146	7	1945_UP
Drug	Methyldopa (L,-) [555-30-6]; Down 200; 19uM; MCF7; HT_HG-U133A	EPS8L1 RTN2 MFAP3L ZSCAN32 CNTNAP2 TLN2 TAB1	2.96e-04	198	146	7	5272_DN
Drug	Cortisone [53-06-5]; Down 200; 11uM; MCF7; HT_HG-U133A	RPS6KA4 TRIOBP EPS8L1 CES2 STK11 SEMA3B TRAPPC14	2.96e-04	198	146	7	7416_DN
Drug	Pantothenic acid calcium salt monohydrate [63409-48-3]; Up 200; 8uM; PC3; HT_HG-U133A	CDHR5 RTN2 CSPG4 LRP1 TLN2 MMP16 MYRF	2.96e-04	198	146	7	4189_UP
Drug	Homosalate [118-56-9]; Up 200; 15.2uM; PC3; HT_HG-U133A	UBR4 NR4A2 PIDD1 EPS8L1 MAGI2 ZSCAN32 PROX1	2.96e-04	198	146	7	3797_UP
Drug	Suprofen [40828-46-4]; Up 200; 15.4uM; HL60; HT_HG-U133A	ACAD10 MFAP3L STK11 BMP8B CSPG4 CES3 ATP2B3	2.96e-04	198	146	7	3005_UP
Drug	iloprost; Down 200; 1uM; SKMEL5; HG-U133A	USP24 NR4A2 DIDO1 ZSCAN32 TLN2 KLK2 WDR77	2.96e-04	198	146	7	496_DN
Drug	Zalcitabine [7481-89-2]; Down 200; 19uM; PC3; HT_HG-U133A	TNIK DPYSL3 ABI3BP MFHAS1 MCL1 ITGB2 ZSCAN32	2.96e-04	198	146	7	4215_DN
Drug	pioglitazone HCl; Down 200; 10uM; MCF7; HT_HG-U133A	NR4A2 PIDD1 ADAM8 CAPN10 MIA2 MMP16 SOS1	2.96e-04	198	146	7	7506_DN
Drug	alpha-estradiol; Down 200; 0.01uM; PC3; HT_HG-U133A	NPR2 PIDD1 EPS8L1 MFAP3L STK11 CES3 MMP16	2.96e-04	198	146	7	4434_DN
Drug	Acetazolamide [59-66-5]; Down 200; 18uM; HL60; HT_HG-U133A	RRP1B CAPN10 ZSCAN32 RNF167 ZNF468 TRAPPC14 DNMT3B	2.96e-04	198	146	7	1850_DN
Drug	SC-560; Down 200; 10uM; PC3; HT_HG-U133A	NPR2 MFHAS1 CAPN10 CELSR2 CSPG4 TRAPPC14 TBCD	2.96e-04	198	146	7	6865_DN
Drug	Solanine alpha [20562-02-1]; Down 200; 4.6uM; PC3; HT_HG-U133A	MCL1 ACAD10 MFAP3L ZSCAN32 LRP1 TLN2 TAB1	3.05e-04	199	146	7	4087_DN
Drug	Oxaprozin [21256-18-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A	RTN2 TEFM ZSCAN32 GMEB1 BEX4 TRAPPC14 MMP16	3.05e-04	199	146	7	4352_DN
Drug	Chenodiol [474-25-9]; Down 200; 10.2uM; MCF7; HT_HG-U133A	TRIOBP DIDO1 EPS8L1 CES2 STK11 SEMA3B TRAPPC14	3.05e-04	199	146	7	7433_DN
Drug	Isopyrin hydrochloride [18342-39-7]; Up 200; 14.2uM; PC3; HT_HG-U133A	TNIK ZSCAN32 USP5 CELSR2 CES3 BEX4 TBCD	3.05e-04	199	146	7	5879_UP
Drug	Sulfamethoxazole [723-46-6]; Up 200; 15.8uM; PC3; HT_HG-U133A	MDM1 NR4A2 ACAD10 CES2 FAM13A OTUD4 TBCD	3.05e-04	199	146	7	7366_UP
Drug	estradiol; Down 200; 0.01uM; PC3; HT_HG-U133A	EPS8L1 ZNF711 STK11 ZSCAN32 CELSR2 CES3 TLN2	3.05e-04	199	146	7	5960_DN
Drug	Proxyphylline [603-00-9]; Up 200; 16.8uM; PC3; HT_HG-U133A	DPYSL3 ADAM8 ITGB2 MFAP3L CELSR2 TLN2 MMP16	3.05e-04	199	146	7	7290_UP
Disease	autosomal recessive nonsyndromic deafness 16 (implicated_via_orthology)	STRC STRCP1	2.47e-05	2	147	2	DOID:0110471 (implicated_via_orthology)
Disease	cortical surface area measurement	TNIK DPYSL3 NPR2 ANK3 ZNF474 MFHAS1 FAT3 TRIOBP TNRC6B TRIM71 CLSTN1 NHSL1 BPGM FAM13A USP38 ARHGAP31 TLN2 CPVL SOS1	4.16e-05	1345	147	19	EFO_0010736
Disease	Moyamoya disease	MAGI2 SBF2 LRP1 MYRF	4.70e-05	40	147	4	MONDO_0016820
Disease	response to anticonvulsant	ANK2 MAGI2 CNTNAP2 SORCS2 SOWAHB	6.82e-05	85	147	5	GO_0036277
Disease	triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	SH2B3 MFHAS1 USP24 CES2 IGF2R CELSR2 MYRF	1.41e-04	225	147	7	EFO_0008317, EFO_0020947
Disease	West Syndrome	UPB1 MAGI2 TBCD	2.27e-04	24	147	3	C0037769
Disease	aortic stenosis	ACTR2 CELSR2 MYRF	4.92e-04	31	147	3	EFO_0000266
Disease	Nonsyndromic genetic hearing loss	MYH9 TRIOBP GRHL2 STRC	5.74e-04	76	147	4	cv:C5680182
Disease	very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	MFHAS1 USP24 CES2 IGF2R CELSR2 ANXA9 MYRF	6.64e-04	291	147	7	EFO_0008317, EFO_0020946
Disease	Ventricular Dysfunction	IGF2R DMD	6.77e-04	8	147	2	C0242973
Disease	very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio	SH2B3 MFHAS1 USP24 IGF2R CELSR2 MYRF	8.88e-04	222	147	6	EFO_0008317, EFO_0020943
Disease	brain connectivity measurement	TNIK DPYSL3 SH2B3 MFHAS1 FAT3 TRIOBP NHSL1 SOS1	9.23e-04	400	147	8	EFO_0005210
Disease	cystatin C measurement	SH2B3 SCAF8 ACAD10 USP5 CSPG4 LRP1 ANXA9 SOS1	9.53e-04	402	147	8	EFO_0004617
Disease	glaucoma	SH2B3 TRIOBP CNTNAP2 DISP3 ANTXR1	1.07e-03	154	147	5	MONDO_0005041
Disease	Muscle Weakness	DMD TBCD	1.08e-03	10	147	2	C0151786
Disease	level of Phosphatidylcholine (O-18:2_16:0) in blood serum	SORCS2 MYRF	1.08e-03	10	147	2	OBA_2045132
Disease	sleep duration, low density lipoprotein cholesterol measurement	USP24 MAGI2 IGF2R CELSR2	1.13e-03	91	147	4	EFO_0004611, EFO_0005271
Disease	apolipoprotein A 1 measurement	MAN2A2 SH2B3 NEIL2 CES2 FAM13A CELSR2 CES3 LRP1 ANXA9 MYRF UVRAG CDH16	1.14e-03	848	147	12	EFO_0004614
Disease	insulin sensitivity measurement, response to polyunsaturated fatty acid supplementation	TNRC6B TLN2	1.32e-03	11	147	2	EFO_0004471, EFO_0009131
Disease	epilepsy (implicated_via_orthology)	TNIK KCNH7 ANK2 SBF2 LRP1	1.38e-03	163	147	5	DOID:1826 (implicated_via_orthology)
Disease	red blood cell density measurement	ACO1 TNRC6B ACAD10 FAM13A SBF2 SORCS2 TJP2 OTUD4 ANTXR1 TAF5L MYRF PROX1	1.56e-03	880	147	12	EFO_0007978
Disease	cholesteryl ester 20:2 measurement	MYRF UVRAG	1.57e-03	12	147	2	EFO_0021440
Disease	fructose measurement	TNIK UBR4	1.85e-03	13	147	2	EFO_0010477
Disease	very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	SH2B3 MFHAS1 USP24 IGF2R CELSR2 MYRF	2.14e-03	264	147	6	EFO_0008317, EFO_0020944
Disease	glycerol-3-phosphate measurement	CNTNAP2 DNMT3B	2.48e-03	15	147	2	EFO_0010488
Disease	triglyceride measurement, high density lipoprotein cholesterol measurement	NEIL2 MFHAS1 IGF2R CELSR2 CNTNAP2 UVRAG	2.58e-03	274	147	6	EFO_0004530, EFO_0004612
Disease	phosphatidylcholine 38:3 measurement	IGF2R MYRF	2.83e-03	16	147	2	EFO_0010385
Disease	IGF-1 measurement, IGFBP-3 measurement	CELSR2 SORCS2	3.19e-03	17	147	2	EFO_0004626, EFO_0004627
Disease	FEV/FEC ratio	MYH9 ZNF474 SCAF8 MCL1 FAM13A ARHGAP31 SBF2 CSPG4 CNTNAP2 LRP1 OTUD4 ANTXR1 CPVL CRB2	3.38e-03	1228	147	14	EFO_0004713
Disease	sphingosine 1-phosphate measurement	SORCS2 DMD	3.58e-03	18	147	2	EFO_0800185
Disease	celiac disease	SH2B3 PTPRK ARHGAP31 KLK2	3.70e-03	126	147	4	EFO_0001060
Disease	ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis	RPS6KA4 SH2B3 STK11 PTPRK MYRF DNMT3B	3.70e-03	295	147	6	EFO_0000384, EFO_0000676, EFO_0000729, EFO_0003898, EFO_0004268
Disease	Headache	LRP1 TJP2 SOS1	4.04e-03	64	147	3	HP_0002315
Disease	pulse pressure measurement	ANK2 MFHAS1 FAT3 TRIOBP TNRC6B MCL1 PCDHA11 ACAD10 SLC39A10 CPNE5 FAM13A SBF2 LRP1 TLN2 DNMT3B	4.11e-03	1392	147	15	EFO_0005763
Disease	white matter hyperintensity measurement	ANK2 ZNF474 MCL1 QRICH2 SBF2 TLN2	4.15e-03	302	147	6	EFO_0005665
Disease	wheezing	AP3B1 MAGI2 USF3	4.22e-03	65	147	3	EFO_0009715
Disease	Calcium channel blocker use measurement	SH2B3 NEIL2 MFHAS1 USP38 SBF2	4.36e-03	213	147	5	EFO_0009930
Disease	hearing loss	KLHDC7B TRIOBP PTPRK	4.60e-03	67	147	3	EFO_0004238

Protein segments in the cluster

Peptide	Gene	Start	Entry
VLSGNRNFEGRVHPN	ACO1	531	P21399
FEGPQVQDGRVVGFH	B3GAT3	226	O94766
NRTRQVDNHVIGDPG	DISP3	1021	Q9P2K9
DHVFPVNDGFQALQG	ANTXR1	196	Q9H6X2
EVQRAPHNGFLSLVG	CSPG4	1871	Q6UVK1
GRQGRNHVDESPVEF	DNMT3B	126	Q9UBC3
QAPTQNEEESRHLGG	BEX4	26	Q9NWD9
GQEGEIGHFDSVPNI	AFTPH	531	Q6ULP2
FLHDEQRGGQEQPFL	HTR3B	326	O95264
DGNLHVTQGAGRFIP	DPYSL3	456	Q14195
QTTGPLELLQFDHGQ	ACAD10	281	Q6JQN1
GFHIFQVPEGGRSQD	CAPN10	576	Q9HC96
EPGGPEQATHFIRAN	NPR2	206	P20594
VFNVQRDTDAPGGHI	CELSR2	1166	Q9HCU4
EDSGRGVQIQAHPSQ	CLSTN1	571	O94985
GDFPAVQKQNDVHRA	DMD	2836	P11532
NGSEVTEQPRGQDHC	ADAM8	91	P78325
IFRGNVNGTFIIHPD	CDHR5	291	Q9HBB8
HGERNVFDGIFSNPI	ATP2B3	991	Q16720
FQPHLINVEGVGVAE	ACTR2	266	P61160
NVGAVPSGQDNIHRF	AP3B1	1031	O00203
NPLAQGFITGIHRQF	RAMP3	86	O60896
LNADVQGIHSENGPV	OTUD4	301	Q01804
PDQEGFFNLLSHVQG	PCP2	21	Q8IVA1
FDVHNEANGIKIGPQ	RAB2B	176	Q8WUD1
QPGTEQHDLIQSGRF	QRICH2	396	Q9H0J4
DQHGQEGLDPNRTRA	QRICH2	956	Q9H0J4
EDGFTPLAVALQQGH	ANK2	161	Q01484
ANFQELAVPVVHDGG	DRAM1	111	Q8N682
PNGRHLFTLDQNNGE	PCDHA11	286	Q9Y5I1
GRHNLFEPEDTGQRV	KLK2	76	P20151
VGLEEQGQNFVRHTP	MFAP3L	261	O75121
QGQNFVRHTPEGQEA	MFAP3L	266	O75121
NHRIQLFGPDGVFLN	TRIM71	721	Q2Q1W2
HESVIGRNPEGQLGF	MAGI2	16	Q86UL8
FHRGQALEALGQAQP	NEIL2	201	Q969S2
QLQPVQQGLFIDGHF	GMEB1	36	Q9Y692
GNQIAVLPDHFGQLS	MFHAS1	351	Q9Y4C4
LFRGTPHDQLVGEQT	SBF2	926	Q86WG5
LSFGPDQLQDLGQHV	CRB2	731	Q5IJ48
SEDNGRNVKGPFNHI	KCNH7	296	Q9NS40
HDFVVGQQEGPADQV	MMS19	21	Q96T76
EGQSLHFPRIQEGDS	HMCN2	1396	Q8NDA2
HGFAPEELVVQVDGQ	HSPB9	61	Q9BQS6
GSFKNAVVQGLEQPH	LRP1	1691	Q07954
PEVRQAIHVGNQTFN	CPVL	336	Q9H3G5
DGFGNPRHSVINVFV	NHSL1	631	Q5SYE7
SGNTGQRPVVFLQHG	LIPF	71	P07098
HRLFLVPVGEEGNAN	FAM214B	461	Q7L5A3
NIAHFGGNPDRVTIF	CES2	211	O00748
QGSLRDPEFQHNVGK	MDM1	646	Q8TC05
GAQEVRNHPFFQGLD	RPS6KA4	291	O75676
RFLSNGHVTIPGQQD	MYH9	301	P35579
TGQELEEAVQNRFHG	ANXA9	241	O76027
LRAVGPHQFLGDQEA	BPGM	226	P07738
QHGLTQEGLFRVNGN	FAM13A	71	O94988
QDQVEQFLARHKGPG	HPDL	241	Q96IR7
QRRPGQSFHVNSEVN	PUM1	191	Q14671
QPHDIQEVTENGLGS	HFM1	246	A2PYH4
GVGHAFQGPTARQEL	ITGAD	286	Q13349
RFDGVPQRFDGPQHQ	PCF11	1086	O94913
THRNQPRGDCDGVQI	ITGB2	391	P05107
IPNFQVHDTGRNMGE	PCDHB14	771	Q9Y5E9
HQRNGQTEDVATGPR	BOD1L1	1496	Q8NFC6
ARVPAHGQVLQVGFS	GASK1A	281	Q9UFP1
QHGGRVNLVFFIDSP	FAM157B	351	P0CG42
FIPDVHFANLQRTGQ	GRHL2	481	Q6ISB3
LGHPVFQTQFGRIAV	UPB1	216	Q9UBR1
QVGHGLQPVEIAAFQ	GUCY2F	1081	P51841
QPNGQIHFSIVNGDR	FAT3	3371	Q8TDW7
GIQPQQFEDQRVHSP	DIDO1	1961	Q9BTC0
EDGFTPLAVALQQGH	ANK3	171	Q12955
VQENQGGVPLEHFIT	MARF1	1041	Q9Y4F3
EVFDQVTQEGAGHDP	LY9	561	Q9HBG7
HQNGGNFPRSQISVL	MAN2A2	36	P49641
VLAFAQQHGEPGLAQ	KLHDC7B	226	Q96G42
FPGNINSDGVVRHEL	CNTNAP2	136	Q9UHC6
QPDVHFFQGLRLGAE	EPS8L1	131	Q8TE68
EHAPGNQGFLDVVAA	CES3	191	Q6UWW8
QANRLPGIFDDVHGS	BMP8B	281	P34820
AHNQRAGAPGIQEAE	CCDC8	441	Q9H0W5
VPQVNGENTERHAQP	SCAF8	1211	Q9UPN6
EEHGFCPVGQFILQN	SLC39A10	791	Q9ULF5
VSHEQPRGGEDAAVQ	SLC38A10	996	Q9HBR0
ARRQQPGQEFNHGLV	NEURL4	61	Q96JN8
EVHTAQSLQGAQPGD	CDH16	616	O75309
DGRVSHEFPLNGNQE	CPNE5	391	Q9HCH3
VGDGVQRNHETAFQG	MCL1	216	Q07820
HPQQSEVFVFGDENG	WDR77	221	Q9BQA1
LELQPHGVAFQQDVG	PIDD1	381	Q9HB75
PHFLRLGDVEVNAGQ	PTPRK	196	Q15262
GNPLDHQITNERGES	MIA2	1171	Q96PC5
KDHVTFNNGGLNRPN	NR4A2	536	P43354
LVRGHQAFDVGQPRD	IGF2R	236	P11717
LQAVHRGDGANPFQA	RTN2	401	O75298
QQGNSVRLFTGHRGP	TAF5L	456	O75529
HARNQNEIIFGLNDG	UVRAG	146	Q9P2Y5
VEHNGVLESEAGQPQ	RRP1B	606	Q14684
LEAAHGPGQANQEIA	TAB1	296	Q15750
DPQDLRHNGNVVVAG	SCHIP1	156	P0DPB3
QALEQLGHQAFRPGQ	RECQL4	471	O94761
LQIPQARFAVNGENH	PROX1	386	Q92786
PIGNHAQRVANFALG	GUCY1B2	451	O75343
QEGLQGFLVEAHPDN	RNF167	51	Q9H6Y7
PVSHSEDVQGAVQGN	SORCS2	1126	Q96PQ0
SINIVEHRENFGPFQ	TEFM	96	Q96QE5
QVPEEEASHNGQRRG	STK11	371	Q15831
KIARDNGPGHNITFQ	SOS1	741	Q07889
QQGHQLAIVNRFPGS	PRORP	521	O15091
RGDGHISQQVPAGAN	SOWAHB	461	A6NEL2
GQEQTPRDFLVHQAG	STRC	121	Q7RTU9
QQGPDGLRKQHQSDV	TRIOBP	2181	Q9H2D6
LPGNVGHQDVKDVQF	APEH	551	P13798
DNERVVGFHVLGPNA	TXNRD1	581	Q16881
PQFRGDIHGRNLSNE	TCEAL1	111	Q15170
NGFAGHINLPDLVQQ	TNIK	921	Q9UKE5
QIARSGVQDQPGQHG	ZNF714	521	Q96N38
GRDNPHFENGETSIV	TJP2	51	Q9UDY2
RNLPQNTGLHDQETG	ZSCAN32	186	Q9NX65
GNPNHDGNDLFLVAV	MMP16	231	P51512
QAFNSPAEHLRQIGG	SPATA46	241	Q5T0L3
PGTQAGHVVFDARQR	SPEM3	1146	A0A1B0GUW6
EEHNFLFQLRGGEQP	TRAPPC14	311	Q8WVR3
GDHNITELPQAVAGR	PPAN	246	Q9NQ55
PGVEGDTHFDQLQDV	SEMA3B	296	Q13214
QQHFELVGVADPGVT	ZNF574	41	Q6ZN55
PFAVVGADQEHLVNG	SEPTIN12	246	Q8IYM1
FQDTAGHQVGVLELP	SERPINE3	236	A8MV23
QGPDAHGVFLVRQSE	SH2B3	381	Q9UQQ2
VSHGNGDQGPAVRQA	USF3	1956	Q68DE3
HVDQIFNNGAPGSLE	ARHGAP31	211	Q2M1Z3
VPLGEFFNNTVHSQG	PKHD1L1	2606	Q86WI1
EGQDPFQRQVGHQVL	USP38	51	Q8NB14
VHAVGQELQVTGPFN	CAD	1186	P27708
HDLDVANARPQGGQD	RUVBL1	241	Q9Y265
PQAFVHPSEQDGERG	THUMPD3	486	Q9BV44
QVAHELQGPDAIVFG	nan	26	Q96MT0
NENGDRHLQQGSESP	USP24	2591	Q9UPU5
SQAGHQGLVDPIQFA	TLN2	1456	Q9Y4G6
GREFGSQSIAIHEPQ	ZNF474	101	Q6S9Z5
GQEQTPRDFLVHQAG	STRCP1	121	A6NGW2
ENVGRQGTFPHGIDI	TBCD	516	Q9BTW9
VRQEPVQFGEIGGHT	ABI3BP	1036	Q7Z7G0
QDSFHRGGVVPLQQF	VRTN	321	Q9H8Y1
EQVFVADLVTGPNGH	ZNF711	126	Q9Y462
IPNGGHIRQESQEQS	UBR4	2746	Q5T4S7
PHIFQSEGKIGNQVE	ZNF468	151	Q5VIY5
HLGQQQQGEEPEGAA	PPP1R1A	91	Q13522
NVHGAQSGSVFQLLP	SIGLEC11	536	Q96RL6
IGKGHPEFSTNRQQD	USP5	421	P45974
GREQAQIHNTDGPKN	TNRC6B	361	Q9UPQ9
QGPGSAVDEHQDNVF	KIAA1522	36	Q9P206
APSQGALQGRRQDEH	RAB34	136	P0DI83
QRFFEGHDINGALEP	MYRF	11	Q9Y2G1